Literature DB >> 21900402

Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling.

Andrew D Patterson1, Olivier Maurhofer, Diren Beyoglu, Christian Lanz, Kristopher W Krausz, Thomas Pabst, Frank J Gonzalez, Jean-François Dufour, Jeffrey R Idle.   

Abstract

There has been limited analysis of the effects of hepatocellular carcinoma (HCC) on liver metabolism and circulating endogenous metabolites. Here, we report the findings of a plasma metabolomic investigation of HCC patients by ultraperformance liquid chromatography-electrospray ionization-quadrupole time-of-flight mass spectrometry (UPLC-ESI-QTOFMS), random forests machine learning algorithm, and multivariate data analysis. Control subjects included healthy individuals as well as patients with liver cirrhosis or acute myeloid leukemia. We found that HCC was associated with increased plasma levels of glycodeoxycholate, deoxycholate 3-sulfate, and bilirubin. Accurate mass measurement also indicated upregulation of biliverdin and the fetal bile acids 7α-hydroxy-3-oxochol-4-en-24-oic acid and 3-oxochol-4,6-dien-24-oic acid in HCC patients. A quantitative lipid profiling of patient plasma was also conducted by ultraperformance liquid chromatography-electrospray ionization-triple quadrupole mass spectrometry (UPLC-ESI-TQMS). By this method, we found that HCC was also associated with reduced levels of lysophosphocholines and in 4 of 20 patients with increased levels of lysophosphatidic acid [LPA(16:0)], where it correlated with plasma α-fetoprotein levels. Interestingly, when fatty acids were quantitatively profiled by gas chromatography-mass spectrometry (GC-MS), we found that lignoceric acid (24:0) and nervonic acid (24:1) were virtually absent from HCC plasma. Overall, this investigation illustrates the power of the new discovery technologies represented in the UPLC-ESI-QTOFMS platform combined with the targeted, quantitative platforms of UPLC-ESI-TQMS and GC-MS for conducting metabolomic investigations that can engender new insights into cancer pathobiology. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21900402      PMCID: PMC3206149          DOI: 10.1158/0008-5472.CAN-11-0885

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  46 in total

1.  Human urinary metabolomic profile of PPARalpha induced fatty acid beta-oxidation.

Authors:  Andrew D Patterson; Ondrej Slanar; Kristopher W Krausz; Fei Li; Constance C Höfer; Frantisek Perlík; Frank J Gonzalez; Jeffrey R Idle
Journal:  J Proteome Res       Date:  2009-09       Impact factor: 4.466

2.  Cerebrospinal fluid steroidomics: are bioactive bile acids present in brain?

Authors:  Michael Ogundare; Spyridon Theofilopoulos; Andrew Lockhart; Leslie J Hall; Ernest Arenas; Jan Sjövall; A Gareth Brenton; Yuqin Wang; William J Griffiths
Journal:  J Biol Chem       Date:  2009-12-07       Impact factor: 5.157

3.  Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets.

Authors:  Sandrine Boyault; David S Rickman; Aurélien de Reyniès; Charles Balabaud; Sandra Rebouissou; Emmanuelle Jeannot; Aurélie Hérault; Jean Saric; Jacques Belghiti; Dominique Franco; Paulette Bioulac-Sage; Pierre Laurent-Puig; Jessica Zucman-Rossi
Journal:  Hepatology       Date:  2007-01       Impact factor: 17.425

4.  Alpha-fetoprotein and tumour size are associated with microvascular invasion in explanted livers of patients undergoing transplantation with hepatocellular carcinoma.

Authors:  Patrick P McHugh; Jeffrey Gilbert; Santiago Vera; Alvaro Koch; Dinesh Ranjan; Roberto Gedaly
Journal:  HPB (Oxford)       Date:  2010-02       Impact factor: 3.647

5.  Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression.

Authors:  H Okabe; S Satoh; T Kato; O Kitahara; R Yanagawa; Y Yamaoka; T Tsunoda; Y Furukawa; Y Nakamura
Journal:  Cancer Res       Date:  2001-03-01       Impact factor: 12.701

6.  Acute myeloid leukaemia presenting as cholestatic hepatitis.

Authors:  F A Wandroo; J Murray; D Mutimer; S Hubscher
Journal:  J Clin Pathol       Date:  2004-05       Impact factor: 3.411

7.  Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma.

Authors:  Elisa Wurmbach; Ying-bei Chen; Greg Khitrov; Weijia Zhang; Sasan Roayaie; Myron Schwartz; Isabel Fiel; Swan Thung; Vincenzo Mazzaferro; Jordi Bruix; Erwin Bottinger; Scott Friedman; Samuel Waxman; Josep M Llovet
Journal:  Hepatology       Date:  2007-04       Impact factor: 17.425

Review 8.  An overview of hepatocellular carcinoma study by omics-based methods.

Authors:  Yunfei Pei; Ting Zhang; Victor Renault; Xuegong Zhang
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2009-01       Impact factor: 3.848

Review 9.  Lysophospholipid activation of G protein-coupled receptors.

Authors:  Tetsuji Mutoh; Jerold Chun
Journal:  Subcell Biochem       Date:  2008

10.  Application of 1H NMR-based metabonomics in the study of metabolic profiling of human hepatocellular carcinoma and liver cirrhosis.

Authors:  Hongchang Gao; Qiang Lu; Xia Liu; Hui Cong; Liangcai Zhao; Huimin Wang; Donghai Lin
Journal:  Cancer Sci       Date:  2009-04       Impact factor: 6.716

View more
  101 in total

Review 1.  Review of mass spectrometry-based metabolomics in cancer research.

Authors:  David B Liesenfeld; Nina Habermann; Robert W Owen; Augustin Scalbert; Cornelia M Ulrich
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-10-04       Impact factor: 4.254

2.  Poisoning with Soman, an Organophosphorus Nerve Agent, Alters Fecal Bacterial Biota and Urine Metabolites: a Case for Novel Signatures for Asymptomatic Nerve Agent Exposure.

Authors:  Derese Getnet; Aarti Gautam; Raina Kumar; Allison Hoke; Amrita K Cheema; Franco Rossetti; Caroline R Schultz; Rasha Hammamieh; Lucille A Lumley; Marti Jett
Journal:  Appl Environ Microbiol       Date:  2018-10-17       Impact factor: 4.792

Review 3.  Pre-S2 Mutant-Induced Mammalian Target of Rapamycin Signal Pathways as Potential Therapeutic Targets for Hepatitis B Virus-Associated Hepatocellular Carcinoma.

Authors:  Chiao-Fang Teng; Han-Chieh Wu; Woei-Cherng Shyu; Long-Bin Jeng; Ih-Jen Su
Journal:  Cell Transplant       Date:  2017-02-14       Impact factor: 4.064

4.  Plasma Lipid Profiling in a Rat Model of Hepatocellular Carcinoma: Potential Modulation Through Quinolone Administration.

Authors:  Mohamed I F Shariff; Joshua M Tognarelli; Matthew R Lewis; Elizabeth J Want; Fatma El Zahra Mohamed; Nimzing G Ladep; Mary M E Crossey; Shahid A Khan; Rajiv Jalan; Elaine Holmes; Simon D Taylor-Robinson
Journal:  J Clin Exp Hepatol       Date:  2015-07-18

5.  A switch in the source of ATP production and a loss in capacity to perform glycolysis are hallmarks of hepatocyte failure in advance liver disease.

Authors:  Taichiro Nishikawa; Nadège Bellance; Aaron Damm; Han Bing; Zhen Zhu; Kan Handa; Mladen I Yovchev; Vasudha Sehgal; Tyler J Moss; Michael Oertel; Prahlad T Ram; Iraklis I Pipinos; Alejandro Soto-Gutierrez; Ira J Fox; Deepak Nagrath
Journal:  J Hepatol       Date:  2014-02-26       Impact factor: 25.083

6.  Bioinformatic and metabolomic analysis reveals miR-155 regulates thiamine level in breast cancer.

Authors:  Sinae Kim; Je-keun Rhee; Hyun Ju Yoo; Hee Jin Lee; Eun Ji Lee; Jong Won Lee; Jong Han Yu; Byung Ho Son; Gyungyup Gong; Sung Bae Kim; Shree Ram Singh; Sei Hyun Ahn; Suhwan Chang
Journal:  Cancer Lett       Date:  2014-12-04       Impact factor: 8.679

7.  Modulation of Lipid Metabolism by Celastrol.

Authors:  Ting Zhang; Qi Zhao; Xuerong Xiao; Rui Yang; Dandan Hu; Xu Zhu; Frank J Gonzalez; Fei Li
Journal:  J Proteome Res       Date:  2019-02-12       Impact factor: 4.466

Review 8.  Liver transplantation for hepatocellular carcinoma - factors influencing outcome and disease-free survival.

Authors:  René Fahrner; Felix Dondorf; Michael Ardelt; Yves Dittmar; Utz Settmacher; Falk Rauchfuß
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

Review 9.  The metabolomic window into hepatobiliary disease.

Authors:  Diren Beyoğlu; Jeffrey R Idle
Journal:  J Hepatol       Date:  2013-05-25       Impact factor: 25.083

10.  LC-MS based serum metabolomics for identification of hepatocellular carcinoma biomarkers in Egyptian cohort.

Authors:  Jun Feng Xiao; Rency S Varghese; Bin Zhou; Mohammad R Nezami Ranjbar; Yi Zhao; Tsung-Heng Tsai; Cristina Di Poto; Jinlian Wang; David Goerlitz; Yue Luo; Amrita K Cheema; Naglaa Sarhan; Hanan Soliman; Mahlet G Tadesse; Dina Hazem Ziada; Habtom W Ressom
Journal:  J Proteome Res       Date:  2012-11-01       Impact factor: 4.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.